Lucky Core Industries Limited
Public listed diversified manufacturer - pharmaceuticals business · Karachi · Pakistan
Publicly listed Pakistani manufacturer whose pharmaceuticals business imports, manufactures, markets and distributes primary- and specialty-care medicines and nutraceuticals.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public listed diversified manufacturer - pharmaceuticals business
- Address
- 5 West Wharf, Karachi 74000, Pakistan · 74000
- Website
- luckycore.com ↗
- Phone
- +92 21 111 100 200
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Etipro | Omeprazole enteric coated pellets | 40 mg | Capsule | 24's | 110040 | PKR 885.15 | PKR 36.88/capsule | 8% above median |
| Etipro | Omeprazole | 40 mg | Capsule | 14's | 110040 | PKR 516.34 | PKR 36.88/capsule | 6% above median |
| Exime | Cefuroxime | 750 mg | Injection | 1's | 026158 | PKR 147.73 | PKR 147.73/vial/unit | 23% below median |
| Expera Forte | Rifampicin + Isoniazid + Ethambutol | 275 mg + 150 mg + 75 mg | Tablet | 100's | 007119 | PKR 1,579.99 | PKR 15.80/tablet | Near median |
| Expera Forte | Rifampicin + Isoniazid + Ethambutol | 75 mg + 75 mg + 75 mg | Tablet | 80's | 007119 | PKR 1,266.06 | PKR 15.83/tablet | No comparator |
| Expera-P Forte | Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | 275 mg + 150 mg + 75 mg + 400 mg | Tablet | 100's | 006915 | PKR 4,081.20 | PKR 40.81/tablet | No comparator |
| ExRange | Meropenem | 1000 mg | IV injection | 1's | 115835 | PKR 4,187.68 | PKR 4,187.68/vial/unit | 8% above median |
| ExRange | Meropenem | 500 mg | Injection | 1's | 115836 | PKR 2,240.41 | PKR 2,240.41/vial/unit | 8% above median |
| Febridol | Paracetamol | 500 mg | Tablet | 200's | 022531 | PKR 693.96 | PKR 3.47/tablet | Near median |
| Febridol 100ml | Paracetamol | 10 mg | IV infusion | 100ml | 080917 | PKR 147.73 | PKR 1.48/mL | No comparator |
| Fortexone | Ceftriaxone | 250 mg | IV injection | 1's | 020272 | PKR 203.62 | PKR 203.62/vial/unit | 9% above median |
| Fortexone | Ceftriaxone | 500 mg | Injection | 1's | 020273 | PKR 346.16 | PKR 346.16/vial/unit | 7% above median |
| Fortexone | Ceftriaxone | 1 g | Injection | 1's | 020274 | PKR 661.77 | PKR 661.77/vial/unit | 10% above median |
| Fortexone | Ceftriaxone | 250 mg | IM injection | 1's | 026159 | PKR 219.42 | PKR 219.42/vial/unit | 12% above median |
| Fortexone | Ceftriaxone | 500 mg | Injection | 1's | 026160 | PKR 375.01 | PKR 375.01/vial/unit | 15% above median |
| Fortexone | Ceftriaxone | 1 g | Injection | 1's | 026161 | PKR 738.05 | PKR 738.05/vial/unit | 23% above median |
| Fortexone | Ceftriaxone | 2 g | Injection | 1's | 084196 | PKR 926.92 | PKR 926.92/vial/unit | 15% above median |
| Fotax | Cefotaxime | 250 mg | Injection | 1's | 020275 | PKR 122.18 | PKR 122.18/vial/unit | 16% above median |
| Fotax | Cefotaxime | 500 mg | Injection | 1's | 020276 | PKR 167.12 | PKR 167.12/vial/unit | Near median |
| Fotax | Cefotaxime | 1 g | Injection | 1's | 020277 | PKR 300.57 | PKR 300.57/vial/unit | Near median |
| Fotax | Cefotaxime | 2 g | Injection | 1's | 084197 | PKR 479.94 | PKR 479.94/vial/unit | 6% above median |
| GRYTIL | Entecavir | 0.5 mg | Tablet | 3x10's | 086344 | PKR 10,539.01 | PKR 351.30/tablet | Near median |
| Hy-Cortisone | Hydrocortisone | 100 mg | Injection | 1's | 024424 | PKR 165.62 | PKR 165.62/vial/unit | 57% above median |
| Hy-Cortisone | Hydrocortisone | 250 mg | Injection | 1's | 024425 | PKR 289.79 | PKR 289.79/vial/unit | 74% above median |
| Hy-Cortisone | Hydrocortisone | 500 mg | Injection | 1's | 024426 | PKR 528.12 | PKR 528.12/vial/unit | 47% above median |
| Hy-Solone | Hydrocortisone | 500 mg | Injection | 1's | 084673 | PKR 1,762.11 | PKR 1,762.11/vial/unit | 391% above median |
| Hy-Solone | Methylprednisolone | 40 mg | Injection | 1's | 088685 | PKR 215.55 | PKR 215.55/vial/unit | 17% above median |
| Hy-Solone | Hydrocortisone | 1000 mg | Injection | 1's | 088686 | PKR 3,050.60 | PKR 3,050.60/vial/unit | No comparator |
| Hy-Solone | Hydrocortisone | 125 mg | Injection | 1's | 088687 | PKR 333.69 | PKR 333.69/vial/unit | No comparator |
| Icef | Cefixime | 100 mg/5 mL | Syrup | 30ml | 110036 | PKR 330.39 | PKR 11.01/mL | Near median |
| Icef | Cefixime | 200 mg/5 mL | Suspension | 30ml | 110037 | PKR 404.16 | PKR 13.47/mL | Near median |
| Icef | Cefixime | 400 mg | Capsule | 5's | 112625 | PKR 592.03 | PKR 118.41/capsule | Near median |
| Inderal | Propranolol | 10 mg | Tablet | 50's | 000531 | PKR 173.81 | PKR 3.48/tablet | 85% above median |
| Inderal | Propranolol | 40 mg | Tablet | 50's | 000538 | PKR 316.00 | PKR 6.32/tablet | 96% above median |
| Ketress | Levamisole | 40 mg | Tablet | 30's | 110477 | PKR 496.90 | PKR 16.56/tablet | 68% above median |
| Linexa | Linezolid | 2 mg/200 mL | IV infusion | 200ml | 070362 | PKR 738.63 | PKR 3.69/mL | No comparator |
| Linexa | Linezolid | 400 mg | Tablet | 12's | 096232 | PKR 2,696.01 | PKR 224.67/tablet | Near median |
| Linexa Suspensiuon | Linezolid | 100 mg/5 mL | Suspension | 120ml | 070363 | PKR 1,227.98 | PKR 10.23/mL | 7% below median |
| LinexaTablet | Linezolid | 600 mg | Tablet | 12's | 073213 | PKR 4,719.87 | PKR 393.32/tablet | Near median |
| Merpen | Meropenem | 500 mg | Powder for solution for injection/infusion | 1's | 095156 | PKR 2,077.37 | PKR 2,077.37/vial/unit | No comparator |
| Merpen | Meropenem | 500 mg | Powder for solution for injection | 1's | 095156 | PKR 2,077.37 | PKR 2,077.37/vial/unit | No comparator |
| Merpen | Meropenem | 1000 mg | Powder for solution for injection | 1's | 095157 | PKR 3,882.93 | PKR 3,882.93/vial/unit | No comparator |
| Moximax | Moxifloxacin | 400 mg | IV infusion | 250ml | 045906 | PKR 1,846.59 | PKR 7.39/mL | Near median |
| Moximax | Moxifloxacin | 400 mg | Tablet | 5's | 045910 | PKR 877.13 | PKR 175.43/tablet | Near median |
| Myrin Forte | Rifampicin + Isoniazid + Ethambutol | 275 mg + 150 mg + 75 mg | Tablet | 80's | 089093 | PKR 1,320.62 | PKR 16.51/tablet | Near median |
| Myrin Forte | Rifampicin + Isoniazid + Ethambutol | 275 mg + 150 mg + 75 mg | Tablet | 100's | 089093 | PKR 1,648.07 | PKR 16.48/tablet | Near median |
| MYRIN Rifampacin | Isoniazid | 150 mg | Tablet | 10X10'S | 089096 | PKR 3,513.73 | PKR 35.14/tablet | No comparator |
| Myrin-P Forte | Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | 150 mg + 75 mg + 400 mg + 275 mg | Tablet | 100's | 089095 | PKR 4,081.20 | PKR 40.81/tablet | 20% above median |
| MYRIN-P Rifampacin | Isoniazid | 120 mg | Tablet | 10x10's | 089092 | PKR 3,397.92 | PKR 33.98/tablet | No comparator |
| Nilstat | Nystatin | 100,000 units/mL | Drops | 50ml | 001554 | PKR 183.05 | PKR 3.66/mL | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.